Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Citi
Merck
Chinese Patent Office
QuintilesIMS
Harvard Business School

Generated: September 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,933,310

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,933,310 protect, and when does it expire?

Patent 6,933,310 protects RADICAVA and is included in one NDA.

This patent has seven patent family members in six countries.

Summary for Patent: 6,933,310
Title: Therapeutic agent for amyotrophic lateral sclerosis (ALS)
Abstract:An object of the present invention is to provide a novel medicament with which motor neuron diseases can be treated. According to the present invention, there is provided a therapeutic agent for motor neuron diseases which comprises 3-methyl-1-phenyl-2-pirazoline-5-on or physiologically acceptable salts thereof as an active ingredient.
Inventor(s): Ikeda; Ken (Tokyo, JP)
Assignee: Mitsubishi Pharma Corporation (Osaka, JP)
Application Number:10/399,961
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 6,933,310

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Mitsubishi Tanabe RADICAVA edaravone SOLUTION;INTRAVENOUS 209176-001 May 5, 2017 RX Yes Yes   Try a Free Trial   Try a Free Trial TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)   Try a Free Trial
Mitsubishi Tanabe RADICAVA edaravone SOLUTION;INTRAVENOUS 209176-002 Nov 15, 2018 RX Yes Yes   Try a Free Trial   Try a Free Trial TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,933,310

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2000-324476Oct 24, 2000
PCT Information
PCT FiledNovember 13, 2000PCT Application Number:PCT/JP00/07994
PCT Publication Date:May 02, 2002PCT Publication Number: WO02/34264

International Family Members for US Patent 6,933,310

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 303808   Try a Free Trial
Germany 60022560   Try a Free Trial
European Patent Office 1405637   Try a Free Trial
Spain 2248144   Try a Free Trial
Japan 3758164   Try a Free Trial
Japan WO2002034264   Try a Free Trial
World Intellectual Property Organization (WIPO) 0234264   Try a Free Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Federal Trade Commission
US Department of Justice
Accenture
Merck
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.